SCHEMBL3529151

SCHEMBL3529151

COC(=O)C(C)(C)OCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1ccc2nc(NC(C)=O)sc2c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 16/20 0.49
DYRK1A Q13627 1/20 0.47
FSCN1 Q16658 1/20 0.47
MTOR P42345 12/20 0.47
POLB P06746 1/20 0.45
PIK3CA P42336 9/20 0.44
PIK3CD O00329 1/20 0.44
PIK3CB P42338 1/20 0.44
PIK3CG P48736 1/20 0.44
PRKDC P78527 1/20 0.44
PIK3C3 Q8NEB9 1/20 0.44
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524710 0.90 AKT1 (0.50) AKT1DYRK1AMTORPIK3CAPIK3CD
SCHEMBL3528038 0.89 LMNA (0.46) KDM4EHPGDMAPK1
SCHEMBL3523578 0.85 AKT1 (0.51) AKT1DYRK1AFSCN1MTORPIK3CA
SCHEMBL3523854 0.84 ALDH1A1 (0.43) AKT1MTORPOLBPIK3CAKDM4E
SCHEMBL3524989 0.83 AKT1 (0.50) AKT1DYRK1AFSCN1MTORPIK3CA
SCHEMBL3527218 0.83 ALDH1A1 (0.43) POLBMAPK1
SCHEMBL3529397 0.79 LMNA (0.49) GAAMAPK1
SCHEMBL3525458 0.78 CCR2 (0.44) NPSR1MAPK1
SCHEMBL3529238 0.78 ACLY (0.41)
SCHEMBL3524492 0.76 ALDH1A1 (0.43) KDM4EHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP AKT1 974/4885DYRK1A 1276/4885FSCN1 3384/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG AKT1 1496/4885DYRK1A 1708/4885FSCN1 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.